Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study in Patients With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) to Characterize the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Debio 4126, a 12-week Prolonged-release Octreotide Formulation

NCT05364944 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT05364944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05364944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study in Patients With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) to Characterize the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Debio 4126, a 12-week Prolonged-release Octreotide Formulation
Lead sponsor
Debiopharm International SA
Phase
Phase 1
Overall status
Terminated
Start date
May 18, 2022
Completion date
December 3, 2024
Enrollment
19 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly, gep-net